Literature DB >> 19189073

Receptor for AGE (RAGE) and its ligands-cast into leading roles in diabetes and the inflammatory response.

Shi Fang Yan1, Ravichandran Ramasamy, Ann Marie Schmidt.   

Abstract

The actors in the pathogenesis of diabetes and its complications are many and multifaceted. The effects of elevated levels of glucose are myriad; among these is the generation of advanced glycation end products (AGEs), the products of nonenzymatic glycoxidation of proteins and lipids. The finding that AGEs stimulate signal transduction cascades through the multiligand receptor RAGE unveiled novel insights into diabetes and its complications. Inextricably woven into AGE-RAGE interactions in diabetes is the engagement of the innate and adaptive immune responses. Although glucose may be the triggering stimulus to draw RAGE into diabetes pathology, consequent cellular stress results in release of proinflammatory RAGE ligands S100/calgranulins and HMGB1. We predict that once RAGE is engaged in the diabetic tissue, a vicious cycle of ligand-RAGE perturbation ensues, leading to chronic tissue injury and suppression of repair mechanisms. Targeting RAGE may be a beneficial strategy in diabetes, its complications, and untoward inflammatory responses.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19189073      PMCID: PMC2659764          DOI: 10.1007/s00109-009-0439-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  92 in total

1.  Serum endogenous secretory RAGE levels are inversely associated with carotid IMT in type 2 diabetic patients.

Authors:  Naoto Katakami; Munehide Matsuhisa; Hideaki Kaneto; Yoshimitsu Yamasaki
Journal:  Atherosclerosis       Date:  2006-07-31       Impact factor: 5.162

2.  Blockade of RAGE suppresses alloimmune reactions in vitro and delays allograft rejection in murine heart transplantation.

Authors:  B Moser; M J Szabolcs; H J Ankersmit; Y Lu; W Qu; A Weinberg; K C Herold; A M Schmidt
Journal:  Am J Transplant       Date:  2007-02       Impact factor: 8.086

3.  The -374 T/A polymorphism in the gene encoding RAGE is associated with diabetic nephropathy and retinopathy in type 1 diabetic patients.

Authors:  E Lindholm; E Bakhtadze; M Sjögren; C M Cilio; E Agardh; L Groop; C-D Agardh
Journal:  Diabetologia       Date:  2006-09-13       Impact factor: 10.122

4.  Hexameric calgranulin C (S100A12) binds to the receptor for advanced glycated end products (RAGE) using symmetric hydrophobic target-binding patches.

Authors:  Jingjing Xie; David S Burz; Wei He; Igor B Bronstein; Igor Lednev; Alexander Shekhtman
Journal:  J Biol Chem       Date:  2006-12-11       Impact factor: 5.157

5.  Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.

Authors:  Hidenori Koyama; Tetsuo Shoji; Shinya Fukumoto; Kayo Shinohara; Takuhito Shoji; Masanori Emoto; Katsuhito Mori; Hideki Tahara; Eiji Ishimura; Ryusuke Kakiya; Tsutomu Tabata; Hiroshi Yamamoto; Yoshiki Nishizawa
Journal:  Arterioscler Thromb Vasc Biol       Date:  2006-11-02       Impact factor: 8.311

6.  Serum levels of sRAGE, the soluble form of receptor for advanced glycation end products, are associated with inflammatory markers in patients with type 2 diabetes.

Authors:  Kazuo Nakamura; Sho-ichi Yamagishi; Hisashi Adachi; Yayoi Kurita-Nakamura; Takanori Matsui; Takafumi Yoshida; Tsutomu Imaizumi
Journal:  Mol Med       Date:  2007 Mar-Apr       Impact factor: 6.354

7.  Structural and functional insights into RAGE activation by multimeric S100B.

Authors:  Thorsten Ostendorp; Estelle Leclerc; Arnaud Galichet; Michael Koch; Nina Demling; Bernd Weigle; Claus W Heizmann; Peter M H Kroneck; Günter Fritz
Journal:  EMBO J       Date:  2007-07-26       Impact factor: 11.598

8.  RAGE activation by S100P in colon cancer stimulates growth, migration, and cell signaling pathways.

Authors:  Maren K Fuentes; Shraddha S Nigavekar; Thiruvengadam Arumugam; Craig D Logsdon; Ann Marie Schmidt; Juliet C Park; Emina H Huang
Journal:  Dis Colon Rectum       Date:  2007-08       Impact factor: 4.585

Review 9.  Masquerader: high mobility group box-1 and cancer.

Authors:  Jessica E Ellerman; Charles K Brown; Michael de Vera; Herbert J Zeh; Timothy Billiar; Anna Rubartelli; Michael T Lotze
Journal:  Clin Cancer Res       Date:  2007-05-15       Impact factor: 12.531

10.  Receptor for advanced glycation end products--soluble form and gene polymorphisms in chronic haemodialysis patients.

Authors:  Marta Kalousová; Marie Jáchymová; Oto Mestek; Magdaléna Hodková; Markéta Kazderová; Vladimír Tesar; Tomás Zima
Journal:  Nephrol Dial Transplant       Date:  2007-03-08       Impact factor: 5.992

View more
  76 in total

Review 1.  [Diabetic maculopathy and retinopathy. Functional and sociomedical significance].

Authors:  J G Garweg; A Wenzel
Journal:  Ophthalmologe       Date:  2010-07       Impact factor: 1.059

2.  Aldose reductase (AKR1B3) regulates the accumulation of advanced glycosylation end products (AGEs) and the expression of AGE receptor (RAGE).

Authors:  Shahid P Baba; Jason Hellmann; Sanjay Srivastava; Aruni Bhatnagar
Journal:  Chem Biol Interact       Date:  2011-01-27       Impact factor: 5.192

3.  Hyperglycemia and advanced glycosylation end products suppress adipocyte apoE expression: implications for adipocyte triglyceride metabolism.

Authors:  Doris Joy Espiritu; Zhi Hua Huang; Yong Zhao; Theodore Mazzone
Journal:  Am J Physiol Endocrinol Metab       Date:  2010-07-20       Impact factor: 4.310

4.  Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice.

Authors:  Yulia Vugmeyster; David DeFranco; Debra D Pittman; Xin Xu
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

5.  Receptor for advanced glycation end products gene polymorphisms in cardiac syndrome X.

Authors:  Burak Önal; Deniz Özen; Bülent Demir; Ahmet G Akkan; Sibel Özyazgan
Journal:  Biomed Rep       Date:  2019-07-22

6.  A receptor-based bioadsorbent to target advanced glycation end products in chronic kidney disease.

Authors:  Yangrong Zhang; Karen A Lapidos; Anca Gal-Moscovici; Stuart M Sprague; Guillermo A Ameer
Journal:  Artif Organs       Date:  2013-11-11       Impact factor: 3.094

Review 7.  Endogenous damage-associated molecular pattern molecules at the crossroads of inflammation and cancer.

Authors:  Geetha Srikrishna; Hudson H Freeze
Journal:  Neoplasia       Date:  2009-07       Impact factor: 5.715

8.  Diabetic conditions promote binding of monocytes to vascular smooth muscle cells and their subsequent differentiation.

Authors:  Li Meng; Jehyun Park; Qiangjun Cai; Linda Lanting; Marpadga A Reddy; Rama Natarajan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-12-11       Impact factor: 4.733

9.  High-glucose and advanced glycosylation end products increased podocyte permeability via PI3-K/Akt signaling.

Authors:  Tae-Sun Ha
Journal:  J Mol Med (Berl)       Date:  2010-01-08       Impact factor: 4.599

10.  Hyperglycemia-induced reactive oxygen species increase expression of the receptor for advanced glycation end products (RAGE) and RAGE ligands.

Authors:  Dachun Yao; Michael Brownlee
Journal:  Diabetes       Date:  2009-10-15       Impact factor: 9.461

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.